As a result, MHC-II+/CD74+ apCAFs may drive divergent immune outcomes: in some contexts, they induce the differentiation of naïve CD4+ T cells into immunosuppressive regulatory T cells (Tregs), thereby enhancing immune evasion; in others, they can stimulate effector CD4+ T cell responses that contribute to anti-tumor immunity. This evidence concerns the gene CD4 and neoplasm.